In 167 adults with advanced FGFR2-rearranged cholangiocarcinoma, first-line pemigatinib gave median PFS 8.3 v 6.8 months with gemcitabine–cisplatin (HR 0.58; nominal P=.0078); median overall survival was similar. Trial closed early.
RCTn = 167
Bekaii-Saab et al. Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial